Literature DB >> 14722263

Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus.

Philippe Blancou1, Nicole Chenciner, Raphaël Ho Tsong Fang, Valérie Monceaux, Marie-Christine Cumont, Denise Guétard, Bruno Hurtrel, Simon Wain-Hobson.   

Abstract

Among the many simian immunodeficiency virus (SIV) immunogens, only live attenuated viral vaccines have afforded strong protection to a natural pathogenic isolate. Since the promoter is crucial to the tempo of viral replication in general, it was reasoned that promoter exchange might confer a novel means of attenuating SIV. The core enhancer and promoter sequences of the SIV macaque 239nefstop strain (NF-kappaB/Sp1 region from -114 bp to mRNA start) have been exchanged for those of the human cytomegalovirus immediate-early promoter (CMV-IE; from -525 bp to mRNA start). During culture of the resulting virus, referred to as SIVmegalo, on CEMx174 or rhesus macaque peripheral blood mononuclear cells, deletions arose in distal regions of the CMV-IE sequences that stabilized after 1 or 2 months of culture. However, when the undeleted form of SIVmegalo was inoculated into rhesus macaques, animals showed highly controlled viremia during primary and persistent infection. Compared to parental virus infection in macaques, primary viremia was reduced by >1,000-fold to undetectable levels, with little sign of an increase of cycling cells in lymph nodes, CD4(+) depletion, or altered T-cell activation markers in peripheral blood. Moreover, in contrast to wild-type infection in most infected animals, the nef stop mutation did not revert to the wild-type codon, indicating yet again that replication was dramatically curtailed. Despite such drastic attenuation, antibody titers and enzyme-linked immunospot reactivity to SIV peptides, although slower to appear, were comparable to those seen in a parental virus infection. When animals were challenged intravenously at 4 or 6 months with the uncloned pathogenic SIVmac251 strain, viremia was curtailed by approximately 1,000-fold at peak height without any sign of hyperactivation in CD4(+)- or CD8(+)-T-cell compartment or increase in lymph node cell cycling. To date, there has been a general inverse correlation between attenuation and protection; however, these findings show that promoter exchange constitutes a novel means to highly attenuate SIV while retaining the capacity to protect against challenge virus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722263      PMCID: PMC321388          DOI: 10.1128/jvi.78.3.1080-1092.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

2.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Medicine. The need for a global HIV vaccine enterprise.

Authors:  Richard D Klausner; Anthony S Fauci; Lawrence Corey; Gary J Nabel; Helene Gayle; Seth Berkley; Barton F Haynes; David Baltimore; Chris Collins; R Gordon Douglas; Jose Esparza; Donald P Francis; N K Ganguly; Julie Louise Gerberding; Margaret I Johnston; Michel D Kazatchkine; Andrew J McMichael; Malegapuru W Makgoba; Giuseppe Pantaleo; Peter Piot; Yiming Shao; Edmund Tramont; Harold Varmus; Judith N Wasserheit
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

4.  Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components.

Authors:  M F Stinski; T J Roehr
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

5.  Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef.

Authors:  E Khatissian; V Monceaux; M C Cumont; M P Kieny; A M Aubertin; B Hurtrel
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef.

Authors:  E T Sawai; M S Hamza; M Ye; K E Shaw; P A Luciw
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.

Authors:  A Seth; I Ourmanov; J E Schmitz; M J Kuroda; M A Lifton; C E Nickerson; L Wyatt; M Carroll; B Moss; D Venzon; N L Letvin; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.

Authors:  R P Johnson; J D Lifson; S C Czajak; K S Cole; K H Manson; R Glickman; J Yang; D C Montefiori; R Montelaro; M S Wyand; R C Desrosiers
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

9.  SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans.

Authors:  Binhua Ling; Ronald S Veazey; Amara Luckay; Cecilia Penedo; Keyu Xu; Jeffrey D Lifson; Preston A Marx
Journal:  AIDS       Date:  2002-07-26       Impact factor: 4.177

10.  Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys.

Authors:  Louis Alexander; Petr O Illyinskii; Sabine M Lang; Robert E Means; Jeffrey Lifson; Keith Mansfield; Ronald C Desrosiers
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  6 in total

1.  Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry.

Authors:  Atze T Das; Chris E Baldwin; Monique Vink; Ben Berkhout
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

Authors:  Agneta von Gegerfelt; Antonio Valentin; Candido Alicea; Koen K A Van Rompay; Marta L Marthas; David C Montefiori; George N Pavlakis; Barbara K Felber
Journal:  J Immunol       Date:  2010-08-11       Impact factor: 5.422

3.  HIV-1 clade promoters strongly influence spatial and temporal dynamics of viral replication in vivo.

Authors:  Mireille Centlivre; Peter Sommer; Marie Michel; Raphaël Ho Tsong Fang; Sandrine Gofflo; Jenny Valladeau; Nathalie Schmitt; Françoise Thierry; Bruno Hurtrel; Simon Wain-Hobson; Monica Sala
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.

Authors:  Robert White; Nicole Chenciner; Gregory Bonello; Mary Salas; Philippe Blancou; Marie-Claire Gauduin
Journal:  Vaccine       Date:  2013-11-25       Impact factor: 3.641

5.  Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs.

Authors:  David O Willer; Yongjun Guan; Mark A Luscher; Bing Li; Rick Pilon; Jocelyn Fournier; Monique Parenteau; Mark A Wainberg; Paul Sandstrom; Kelly S MacDonald
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

6.  Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control.

Authors:  Xue Zhou; Monique Vink; Ben Berkhout; Atze T Das
Journal:  Retrovirology       Date:  2006-11-09       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.